Literature DB >> 18697452

[Hyper IgE syndrome. Opportune diagnosis and management].

Celia Vega Orozco1, Luiana Hernández Velásquez, Nora Hilda Segura Méndez, Bernardo Augusto, Torres Salazar.   

Abstract

The hyperimmunoglobulin E syndrome was discribed for Buckley, and it also called the Job syndrome. There are two types: dominant autosomal and recessive autosomal. It is a primary, rare and complex immunodeficiency, characterized clinically by recurrent skin abscesses for Staphylococcus aureus, recurrent pneumonia, and pneumatoceles, hypereosinophylia, high serum levels of immunoglobulin E (> 2,000 Ul/mL), early eczema and late loss of primary dentition. Recently a STAT3 mutation has been described as origin of dominant autosomal hyperimmunoglobulin E syndrome. Since 1972, 250 cases have been reported around the world. The diagnosis is done with the Grimbacher criteria and the prognosis depends on the opportune diagnosis and treatment. The incidence is same in women and men. The differential diagnosis is with allergic bronchopulmonary aspergillosis, chronic granullomatose disease, T cell lymphoma, and atopic dermatitis. The treatment is with prophylactic antibiotic, intravenous immunoglobulin or recombinant INF gamma.

Entities:  

Mesh:

Year:  2008        PMID: 18697452

Source DB:  PubMed          Journal:  Rev Alerg Mex        ISSN: 0002-5151


  2 in total

1.  Anesthetic management in a child with Job's syndrome.

Authors:  Prasad Kulkarni; Riddhi Shah; V N Priyanka
Journal:  Anesth Essays Res       Date:  2012 Jul-Dec

2.  Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome.

Authors:  Cesar Daniel Alonso-Bello; María Del Carmen Jiménez-Martínez; María Eugenia Vargas-Camaño; Sagrario Hierro-Orozco; Mario Alberto Ynga-Durand; Laura Berrón-Ruiz; Julio César Alcántara-Montiel; Leopoldo Santos-Argumedo; Diana Andrea Herrera-Sánchez; Fernando Lozano-Patiño; María Isabel Castrejón-Vázquez
Journal:  Case Reports Immunol       Date:  2019-07-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.